Health Catalyst (NASDAQ:HCAT) Given In-Line Rating at Evercore ISI

Evercore ISI reissued their in-line rating on shares of Health Catalyst (NASDAQ:HCAT) in a report issued on Wednesday morning, MarketBeat Ratings reports. They currently have a $4.00 target price on the stock, down from their prior target price of $6.00.

HCAT has been the topic of a number of other reports. Stifel Nicolaus cut their price objective on shares of Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a report on Thursday, February 27th. Citigroup decreased their price objective on Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Wells Fargo & Company dropped their price objective on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research note on Tuesday, January 21st. KeyCorp raised Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a research note on Wednesday, January 8th. Finally, Stephens cut their price target on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, March 6th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.73.

Health Catalyst Trading Up 2.6 %

NASDAQ HCAT opened at $3.93 on Wednesday. Health Catalyst has a 52 week low of $3.60 and a 52 week high of $9.24. The company has a market cap of $275.93 million, a price-to-earnings ratio of -2.91 and a beta of 1.43. The business has a 50 day moving average price of $4.65 and a 200-day moving average price of $6.51. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Insider Transactions at Health Catalyst

In other news, COO Daniel Lesueur sold 16,902 shares of Health Catalyst stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total value of $76,397.04. Following the completion of the transaction, the chief operating officer now owns 216,250 shares of the company’s stock, valued at $977,450. The trade was a 7.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Benjamin Landry sold 13,827 shares of the company’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $4.55, for a total transaction of $62,912.85. Following the completion of the transaction, the general counsel now owns 160,437 shares in the company, valued at approximately $729,988.35. The trade was a 7.93 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 54,030 shares of company stock valued at $263,269. Corporate insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Quantbot Technologies LP purchased a new position in shares of Health Catalyst in the 4th quarter worth $29,000. Group One Trading LLC increased its position in Health Catalyst by 107.6% during the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock valued at $31,000 after acquiring an additional 2,260 shares during the last quarter. Aquatic Capital Management LLC bought a new position in Health Catalyst in the fourth quarter valued at about $63,000. Quadrature Capital Ltd purchased a new position in Health Catalyst in the third quarter worth about $84,000. Finally, Stoneridge Investment Partners LLC purchased a new position in Health Catalyst in the fourth quarter worth about $77,000. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.